APGE

Apogee Therapeutics, Inc. Common Stock

NASDAQ: APGE · HEALTHCARE · BIOTECHNOLOGY

$134.20

+0.02% today

Updated 2026-07-29

Market cap

$10.07B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.33

Dividend yield

—

52W range

$34 – $134

Volume

3.0M

Market cap

$10.07B

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-4.33

Dividend yield

—

52W range

$34 – $134

Volume

3.0M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

8.5

Quality

3.0

Profitability

5.0

Valuation

C+

2/9

Piotroski F-Score

Weak

15.5

Altman Z-Score

Safe zone

—

Industry rank

—

View all highly rated stocks (75+) →206 stocks currently score above 75

Price targets

Analyst target

$130.53

-2.73%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy15 Buy4 Hold0 Sell0 Strong Sell

Price chart

Stock snapshot

Strengths

+ Altman Z 15.48 — safe zone

+ Debt/equity 0.01x — low leverage

Risks

- Piotroski 2/9 — weak financial health

- Thin margins at 0.00%

- Negative free cash flow $-55.57M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-39.78M	$-83.98M	$-182.15M	$-255.84M	$-74.11M
EPS	—	—	—	—	$-4.33
Free cash flow	$-16.43M	$-74.93M	$-172.33M	$-232.60M	$-55.57M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
APGE	$10.07B	26	4.3	3.0	5.0	8.5	—	Avoid
LLY	$1.02T	76	10.0	10.0	4.3	6.0	—	Strong Buy
JNJ	$615.36B	57	4.7	8.5	4.3	6.0	—	Buy
ABBV	$447.53B	63	4.0	8.0	4.7	5.0	-78.83%	Buy
UNH	$391.69B	62	7.3	5.5	4.0	6.0	-30.51%	Buy
MRK	$307.25B	50	3.3	8.0	2.7	5.0	-62.28%	Hold

Smart narrative

Apogee Therapeutics, Inc. Common Stock trades at $134.20. Our Smart Value Score of 26/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of 15.48, it sits in the safe zone.

Frequently asked questions

What is Apogee Therapeutics, Inc. Common Stock's stock price?

Apogee Therapeutics, Inc. Common Stock (APGE) trades at $134.20.

Is Apogee Therapeutics, Inc. Common Stock overvalued?

Apogee Therapeutics, Inc. Common Stock carries a Smart Value Score of 26/100 (Grade F), which we rate Strong Sell. That score blends growth, quality, and valuation into one read.

What is the price target of Apogee Therapeutics, Inc. Common Stock (APGE)?

The 12-month analyst consensus target is $130.53, about 2.7% below the current $134.20. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.

Altman Z-Score?

Apogee Therapeutics, Inc. Common Stock's Altman Z-Score is 15.48, which places it in the safe zone. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

Quick metrics

P/S ratio—

ROE-21.87%

Beta0.33

50D MA$102.39

200D MA$78.45

Shares out0.06B

Float0.06B

Short ratio—

Avg volume3.0M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

APGE vs LLY →APGE vs JNJ →APGE vs ABBV →Stock screener →